This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de Abiomed

Salud financiera controles de criterios 6/6

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	-62.2x
Efectivo	US$820.37m
Patrimonio	US$1.54b
Total pasivo	US$156.76m
Activos totales	US$1.70b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: AIO's short term assets ($1.1B) exceed its short term liabilities ($134.1M).

Pasivo a largo plazo: AIO's short term assets ($1.1B) exceed its long term liabilities ($22.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: AIO is debt free.

Reducción de la deuda: AIO had no debt 5 years ago.

Cobertura de la deuda: AIO has no debt, therefore it does not need to be covered by operating cash flow.

Cobertura de intereses: AIO has no debt, therefore coverage of interest payments is not a concern.

This company listing is no longer active

Salud financiera de hoja de balance de Abiomed

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Second quarter 2023 earnings released: EPS: US$2.34 (vs US$1.25 in 2Q 2022)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold €1.0m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) acquired all the assets and business from Sensera, Inc. for $7.5 million on January 4, 2022.

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold €4.5m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: €310

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: €267

New 90-day low: €216

Second quarter 2021 earnings released: EPS US$1.38

Revenue beats expectations

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

New 90-day high - €263

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera